Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in heavily pretreated patients with hematological malignancies. (2009). Hematology Meeting Reports, 1(8). https://doi.org/10.4081/hmr.v1i8.297